🏛️ Verified NIH Record • Updated 2026-08-20
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma (NCT04106219)
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Eli Lilly and Company
🩺 Plain-English Summary (8th-Grade Level)
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
Who can join: Review the eligibility criteria below.
Location: UCSF Medical Center at Mission Bay — San Francisco, California
Age range: 2 Years to 21 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- UCSF Medical Center at Mission Bay — San Francisco, California
- Children's Hospital Colorado — Aurora, Colorado
- University of Chicago - Comer Children's Hospital — Chicago, Illinois
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Cincinnati Childrens Hospital Medical Center — Cincinnati, Ohio
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Texas Childrens Hospital — Houston, Texas
- Perth Children's Hospital — Perth, Western Australia
- UZ Gent — Ghent, Oost-Vlaanderen
- Centre Leon Berard — Lyon, Auvergne-Rhône-Alpes
- Institut Curie — Paris,
- Universitätsklinikum Köln — Cologne,
- Istituto Nazionale dei Tumori — Milan, Lombardy
- National Cancer Center Hospital — Chuo-ku, Tokyo
- Hospital Universitari Vall d'Hebron — Barcelona, Barcelona [Barcelona]
- Hospital Infantil Universitario Niño Jesús — Madrid,
- Alder Hey Children's Hospital — Liverpool,
📞 Contact the Study Coordinator
Phone: (877) 827-3222
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neuroblastoma
- Open-Label Study of 18F-mFBG for Imaging Neuroblastoma — Los Angeles, California
- Neuroblastoma Precision Trial — Los Angeles, California
- Neuroblastoma Maintenance Therapy Trial — Birmingham, Alabama
- Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow — Indianapolis, Indiana
- A Study of N9 Chemotherapy in Children With Neuroblastoma — New York, New York
Explore by condition: All Neuroblastoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.